News | Cath Lab | May 24, 2016

SCAI 2016 Late-breaking Trial Presesentations

The latest interventional cardiology trial data presented at the Society for Cardiovascular Angiography and Interventions 2016 Scientific Sessions

 

The Society for Cardiovascular Angiography and Interventions (SCAI) 2016 Scientific Sessions took place May 4-7, 2016 in Orlando, Fla. The event included data from clinical trials on some of the latest advances in interventional cardiology. The late-breaking clinical trials presentations include the following, including links to related stories on these trials:

Wednesday, May 4, 1:15 - 2:15 p.m. Eastern Time

• Effect of the AVERT Contrast Modulation System on Contrast Dose Reduction and Acute Kidney Injury After Coronary Angiography and PCI, presented by Roxana Mehran, M.D., FSCAI.

• Clinical Evaluation of the Cadence Device in the Acoustic Detection of Coronary Artery Disease: The TURBULENCE Study, presented by Joseph Thomas, M.D., FSCAI.

• Demonstration of the Safety and Feasibility of Robotically Assisted Percutaneous Coronary Intervention in Complex Coronary Lesions: Results of the Complex Robotically Assisted Percutaneous Coronary Intervention (CORA-PCI) Trial, presented by Ehtisham Mahmud, M.D., FSCAI.

• Risk Directed Interventions in Percutaneous Coronary Intervention (PCI):  An Enterprise Approach for Reducing Bleeding Events, presented by Jerome E. Granato, M.D.

 

Thursday, May 5, 10:30 - 11:30 a.m. Eastern Time
 Plaque Morphology Predictors of Side Branch Occlusion after Provisional Stenting in Coronary Bifurcation Lesion: Results of Optical Coherence Tomography Bifurcation Study (ORBID), presented by Annapoorna Kini, M.D.

• Final Results for THE ATHENA TRIALS: Autologous Adipose Derived Regenerative Cells (ADRCs) for Refractory Chronic Myocardial Ischemia with Left Ventricular (LV) Dysfunction, presented by Timothy D. Henry, M.D., MSCAI.

• Efficacy of STENTYS Self-Apposing Bare Metal Nitinol Stents in Patients Undergoing Primary PCI: Results from the APPOSITION V Trial, presented by Roxana Mehran, M.D., FSCAI.

• Final Results for the Renew Trial: A Phase 3, Randomized, Double Blinded, Active-Controlled, Unblinded Standard of Care Study Assessing the Efficacy and Safety of Intramyocardial Autologous CD34+ Cell Administration in Patients with Refractory Angina, presented by Timothy D. Henry, M.D., MSCAI.

 

Friday, May 6 | 9:00 a.m. to 10:00 a.m. Eastern Time
• Sex Based Differences in Outcomes With Transcatheter Aortic Valve Therapy: From the STS/ACC TVT Registry, presented by Roxana Mehran, M.D., FSCAI.

• Sex-Based Differences in Patients Less than 50 Years of Age Undergoing PCI for Acute Coronary Syndromes, presented by Jaya Chandrasekhar, MBBS.

• Moderate vs. General Anesthesia for Transcatheter Aortic Valve Replacement: An STS/ACC Transcatheter Valve Therapy Registry Analysis, presented by Jay Giri, M.D., MPH.

• Sex Based Differences in Outcomes with Bivalirudin or Unfractionated Heparin for Transcatheter Aortic Valve Replacement: Results from the BRAVO 3 Randomized Trial, presented by Anita W. Asgar, M.D.

For more information on the late-breaking trials and featured clinical research being presented at the meeting, visit: www.scai.org/SCAI2016LBCT.  

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init